COMPASS Pathways Plc CMPS

Healthcare Biotechnology

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

NDAQ:CMPS - Post by User

COMPASS Pathways Plc > Numinus currently going for ATH

<< Previous

Bullboard Posts

Next >>

Post by MrHappy420on Nov 29, 2020 8:29am

734 Views

Post# 31996326

Numinus currently going for ATH

With a market cap of nearly 80mm, Numinus has A LOT of catching up to do before its par with MindMed.
Do not discount the fact that Numi is the only publicly traded Canadian company with the license to buy sell and grow mushrooms, along with other compounds.

let's have a great week!

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now